img

United States Direct-To-Consumer (DTC) Testing Market By Genetic Testing (Ancestry Testing, Health Risk Assessment, Pharmacogenomics), Health And Wellness Testing (Nutritional Testing, Fitness and Exercise Testing, Metabolic Testing), Carrier Screening (Preconception Carrier Screening, Prenatal Carrier Screening), & Region for 2024-2031


Published on: 2024-08-06 | No of Pages : 320 | Industry : latest updates trending Report

Publisher : MIR | Format : PDF&Excel

United States Direct-To-Consumer (DTC) Testing Market By Genetic Testing (Ancestry Testing, Health Risk Assessment, Pharmacogenomics), Health And Wellness Testing (Nutritional Testing, Fitness and Exercise Testing, Metabolic Testing), Carrier Screening (Preconception Carrier Screening, Prenatal Carrier Screening), & Region for 2024-2031

United States Direct-To-Consumer (DTC) Testing Market Valuation – 2024-2031

United States direct-to-consumer (DTC) testing market, increased awareness efforts on the benefits of genomic screening are expected to boost the adoption of low-cost DTC genetic testing. Furthermore, market players and regulatory agencies are working to promote the testing and integration of these services in healthcare settings to lower overall healthcare spending, which is helping to drive market expansion. The market size surpass USD 261.63 Million valued in 2024 to reach a valuation of around USD 768.75 Million by 2031.

The market for DTC testing has expanded as a result of advancements in genetic sequencing, data analytics, and personalized medicine, which have increased its accessibility, accuracy, and affordability. Direct-to-consumer (DTC) testing meets both requirements by eliminating the need for laboratory visits or doctor referrals, allowing people to get health-related information from the comfort of their own homes. The rising demand for United States direct-to-consumer (DTC) testing is enabling the market grow at a CAGR of 15.91% from 2024 to 2031.

United States Direct-To-Consumer (DTC) Testing MarketDefinition/ Overview

 In the United States, direct-to-consumer (DTC) testing refers to genetic testing services that are promoted directly to customers rather than through a healthcare provider. These tests provide consumers with information about their genetic predispositions, ancestry, health features, and, in certain cases, carrier status for specific genetic disorders via online platforms or retail locations.

Customers usually gather their DNA samples (such as saliva or cheek swabs) at home and send them to the testing business for examination. The results are then delivered directly to the consumer, frequently accompanied by interpretation and educational elements. DTC testing bypasses regular healthcare systems, allowing people to make educated decisions about their health and heritage based on genetic information gained through these tests.

The Direct-to-Consumer (DTC) testing industry in the United States has grown significantly, owing to advances in genetic technology and increased consumer interest in personalized healthcare insights. DTC testing enables individuals to obtain genetic information about their ancestry, health features, and potential genetic predispositions directly from firms such as 23andMe, AncestryDNA, and MyHeritage DNA. This convenience appeals to customers who want to learn about their genetic heritage and associated health risks without involving healthcare providers.

The market’s growth has been aided by strong online platforms that allow customers to purchase tests, receive results electronically, and access interpretation services. However, the industry has also experienced attention questioning the accuracy, privacy, and ethical implications of genetic testing, resulting in regulatory monitoring and consumer education campaigns to promote transparency and responsible use of genetic information.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Consumer Demand for Personalized Health and Ancestry Information Drive the United States Direct-To-Consumer (DTC) Testing Market?

Consumer desire for tailored health and ancestry information is expected to drive the US Direct-to-Consumer (DTC) testing market dramatically. This need is driven by a growing tendency toward proactive healthcare management, as well as an increased interest in understanding genetic predispositions to diseases and health characteristics. Consumers are increasingly empowered to take control of their health by using genetic testing services that provide information about potential risks for problems such as cancer, cardiovascular disease, and genetic abnormalities. The capacity to discover such information enables people to make informed decisions about lifestyle modifications, preventive screenings, and healthcare management measures.

The appeal of DTC testing goes beyond health to ancestry exploration. Many consumers are keen to learn about their genetic background, tracing their ancestors and comprehending their genetic variety. Companies such as 23andMe and AncestryDNA respond to this desire by giving precise ethnicity estimations and historical movement patterns using genetic data.

The ease of obtaining DNA samples at home and receiving detailed findings online has democratized access to this information, making it available to a wider range of people. As consumer awareness develops and technology developments improve the accuracy and scope of DTC testing, the market is likely to grow further, fueled by the attractiveness of personalized health insights and ancestry exploration.

Will the Complex Landscape of Regulatory Oversight and Interpretation of Genetic Testing Results Impact the Demand for the United States Direct-To-Consumer (DTC) Testing Market?

The complicated environment of regulatory oversight and interpretation of genetic testing findings has a substantial impact on demand in the US Direct-to-Consumer (DTC) testing business. Regulatory authorities such as the FDA (Food and Drug Administration) and CMS (Centers for Medicare and Medicaid Services) are critical in ensuring the quality, accuracy, and ethical implications of genetic testing services.

Their regulations require DTC testing organizations to comply with tight criteria for test validity, data protection, and the disclosure of genetic information to consumers. Changes or updates to regulatory requirements might impact consumer trust and confidence in DTC testing services, impacting market dynamics.

Interpreting genetic testing data presents obstacles that can influence customer demand. While DTC testing can reveal useful information about an individual’s genetic predispositions and ancestry, effectively interpreting the results takes specific knowledge and skills. Genetic counselors and healthcare experts play critical roles in educating consumers about the consequences of their genetic data, such as potential health concerns and the limitations of genetic testing. Variant categorization, false positives/negatives, and the dynamic nature of genetic research can all make it difficult to evaluate results and make informed consumer decisions.

As a result, the availability and accessibility of skilled professionals to help customers understand their DNA test results are critical elements that can impact demand and acceptance of DTC testing services in the United States.

Category-Wise Acumens

Will the Health Risk Assessment Propel the Segment of the United States Direct-To-Consumer (DTC) Testing Market?

Health risk assessment is critical to the growth of the US Direct-to-Consumer (DTC) testing business. Consumers are increasingly interested in learning about their genetic predispositions to a variety of health concerns, including common ailments like diabetes and heart disease, as well as more complicated genetic disorders like breast cancer and Alzheimer’s. DTC testing allows people to gain genetic information that can help them develop proactive health management measures. For example, knowing one’s genetic risk factors might help people make informed decisions about lifestyle changes, early screenings, and preventative healthcare interventions.

The convenience and accessibility of DTC testing have broadened the scope of health risk assessment services. Customers can simply buy genetic testing kits online or in stores, collect DNA samples at home with saliva or cheek swabs, and submit them to testing businesses for examination. Results are often supplied electronically, along with full reports and interpretation services to assist people in understanding their genetic risks. This direct access to health-related genetic information circumvents traditional healthcare processes, allowing individuals to play a more active part in managing their health outcomes. As consumer awareness rises and genetic testing technology advances, the demand for health risk assessment via direct-to-consumer testing is likely to drive significant market growth.

Will Fitness and Exercise Testing Accelerate Significant Demand for the United States Direct-To-Consumer (DTC) Testing Market?

Fitness and exercise testing has the potential to drive significant demand for the US Direct-to-Consumer (DTC) testing market, while its impact may differ from that of health and ancestry testing. Consumers are increasingly interested in learning how their genetic composition affects their athletic ability, metabolism, and response to exercise. DTC testing firms are rapidly offering genetic tests that provide information about fitness traits such as muscle composition, aerobic ability, and injury risk. Individuals can use this information to customize their workout routines, optimize training tactics, and potentially improve their sports performance.

The implementation of fitness and exercise-focused DTC testing confronts a number of hurdles. Consumers may consider the practical application of fitness genetic insights as less immediate or essential than health-related genetic testing, which can have a direct impact on medical decisions and preventive healthcare actions. Furthermore, scientific understanding of how genetics influences fitness attributes is still developing, and genetic predispositions are just one of many factors that influence athletic performance and fitness outcomes.

Furthermore, worries regarding privacy, genetic information accuracy, and the ethical implications of using genetic data for fitness improvement may impact consumer trust and adoption rates. Nevertheless, as research develops and consumer awareness grows, the potential for fitness and exercise testing to contribute to the expansion of the DTC testing business remains a promising area for innovation and consumer engagement.

Gain Access into United States Direct-To-Consumer (DTC) Testing Market Report Methodology

Country/Region-wise Acumens

Will the High Disposable Income of North American United States Direct-To-Consumer (DTC) Testing Drive the Market?

The high discretionary income in North America, notably in the United States, is likely to drive the Direct-to-Consumer (DTC) testing industry. With more discretionary buying power, North American customers are more ready and able to invest in DTC testing services that provide individualized healthcare and ancestry information. The low cost of these tests, combined with the perceived value of learning about genetic predispositions to diseases and ancestry, make them appealing possibilities for those wishing to better understand their health risks and heritage.

North America’s high disposable income levels promote a culture of wellness and proactive healthcare management. Consumers are increasingly valuing preventative healthcare and tailored medicine, seeing genetic testing as a proactive step toward knowing and minimizing health risks. This demographic trend is consistent with the increased emphasis on individualized healthcare solutions and the use of genetic information in personalized treatment strategies. As a result, direct-to-consumer testing companies such as 23andMe and AncestryDNA are well-positioned to capitalize on North American customers’ willingness to invest in their health and heritage via convenient, accessible, and informative genetic testing services.

Competitive Landscape

The United States direct-to-consumer (DTC) testing market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the market include

  • 23andMe
  • Family Tree DNA
  • Ancestry
  • Genesis HealthCare
  • EasyDNA,
  • Veritas
  • Myriad Genetics Inc.
  • Full Genomes Corporation, Inc
  • Living DNA Ltd.
  • Color Health, Inc.

Latest Developments

  • In April 2023, Genesis Healthcare Co.’s GeneLife brand will introduce Haplo 3.0 in Japan marking a significant advance to its ancestry services.
  • In July 2023, Quest Diagnostics debuted its first DTC-GT, Genetic Insights. The test analyzes a saliva sample to determine the risk of up to 24 genetically inheritable diseases, including colon and breast cancer, blood and heart issues, cystic fibrosis carrier status, sickle cell anemia, and Tay-Sachs disease.

Report Scope

REPORT ATTRIBUTESDETAILS
Study Period

2021-2031

Growth Rate

CAGR of ~15.91% from 2024 to 2031

Base Year for Valuation

2024

Historical Period

2021-2023

Forecast Period

2024-2031

Quantitative Units

Value in USD Million

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Genetic Testing
  • Health And Wellness Testing
  • Carrier Screening
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

23andMe, Family Tree DNA, Ancestry, Genesis HealthCare, EasyDNA,, Veritas, Myriad Genetics Inc., Full Genomes Corporation, Inc, Living DNA Ltd., Color Health, Inc.

Customization

Report customization along with purchase available upon request

United States Direct-To-Consumer (DTC) Testing Market, By Category

Genetic Testing

  • Ancestry Testing
  • Health Risk Assessment
  • Carrier Testing
  • Pharmacogenomics

Health and Wellness Testing

  • Nutritional Testing
  • Fitness and Exercise Testing
  • Metabolic Testing
  • Hormone Testing

Carrier Screening

  • Preconception Carrier Screening
  • Prenatal Carrier Screening

Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.

Pivotal Questions Answered in the Study

Some of the key players leading in the market include 23andMe, Family Tree DNA, Ancestry, Genesis HealthCare, EasyDNA, Veritas, Myriad Genetics Inc., Full Genomes Corporation Inc., Living DNA Ltd., and Color Health Inc.
The United States direct-to-consumer (DTC) testing market is estimated to grow at a CAGR of 15.91% during the forecast period.
The United States direct-to-consumer (DTC) testing market was valued at around USD 261.63 Million in 2024.
<div class="panel-headi

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )